首页> 外文期刊>International Journal of Psychiatry in Medicine >Updates in insomnia diagnosis and treatment
【24h】

Updates in insomnia diagnosis and treatment

机译:失眠诊断和治疗的更新

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction Insomnia is the most commonly reported sleep disorder and remains undertreated in many patients. New changes to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, have changed the way insomnia is diagnosed. In patients who suffer from insomnia, a number of available treatment options exist including both behavioral therapy and medications. Literature Review: First line therapy for insomnia should always include behavioral modifications such as sleep hygiene and insomnia-oriented cognitive behavioral therapy. In patients deemed to need pharmacotherapy, first line medications include nonbenzodiazepine hypnotics (i.e., z-drugs) and antidepressants depending on the patients’ needs and comorbidities. The risk of next day impairment, parasomnias, and central nervous system depression are some of the most feared side effects with z-drugs. Second line drug therapy includes melatonin and suvorexant. Several concerns exist for suvorexant similar to other insomnia medications, but melatonin remains one of the safest medication alternatives. Other medication options such as benzodiazepines, antihistamines, and antipsychotics should rarely be used because of weak effectiveness data or serious safety concerns. Discussion The most appropriate treatment plan needs to be tailored to meet the needs of individual patients. Many patient factors (e.g., age, other comorbidities, specific problems with sleep) need to be considered before prescribing drug therapy for patients suffering from insomnia. Medications with the best evidence and fewest safety concerns should be prioritized when clinicians work with patients to determine the most appropriate treatment plan. Conclusions Nondrug treatment should be the emphasis for managing insomnia, but several options exist for patients needing multimodal therapy to improve their symptoms and maximize their quality of life. Z-drugs and antidepressants are first line medications options, but other options may be considered when tailored to individual patients. Medications should only be used intermittently and short term until nondrug treatments help to change a patient’s sleep routine.
机译:引入失眠是最常见的睡眠障碍,并且在许多患者中仍然存在。精神障碍诊断和统计手册的新变化,第五版,改变了失眠诊断的方式。在患有失眠症的患者中,存在许多可用的治疗方案,包括行为治疗和药物。文献综述:失眠的第一线疗法应始终包括行为修改,例如睡眠卫生和失眠导向的认知行为治疗。在被视为需要药物治疗的患者中,第一线药物包括非苯并二氮杂戊类催眠药(即,Z-药物)和抗抑郁药,这取决于患者的需求和合并症。下天损伤,副癌症和中枢神经系统抑郁症的风险是Z-药物中最令人担忧的副作用。二线药物治疗包括褪黑激素和Suvorexant。对于类似于其他失眠药物的Suvorexant存在一些担忧,但褪黑素仍然是最安全的药物替代品之一。其他药物选项如苯二氮卓类药物,抗组胺药和抗透视性,因为有效性较弱或严重的安全问题,应该很少被使用。讨论需要量身定制最合适的待遇计划以满足个体患者的需求。在规定失眠症的患者的药物治疗之前,需要考虑许多患者因素(例如,年龄,其他同血症,睡眠的特定问题)。当临床医生与患者合作以确定最合适的治疗计划时,应优先考虑最佳证据和最少的安全问题。结论不良治疗应该是管理失眠的重点,但需要多式峰治疗患者提高其症状并最大化其生活质量的患者存在几种选择。 Z-药物和抗抑郁药是第一线药物选择,但在为个体患者身份定制时可能会考虑其他选择。药物应该只能间歇性,短期使用,直到非鲁格治疗有助于改变患者的睡眠常规。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号